AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable muscle-invasive bladder cancer (MIBC).

Madrid - Ghali Belkahia, a young Moroccan physician who excels in the demanding world of high-precision urological surgery, recently contributed to the success of an unprecedented medical advancement ...

The study looked at infections caused by Aspergillus fumigatus, which tops the World Health Organization's list of worrying fungal diseases. Other research news is on an experimental treatment that ...